Education
About Us
Working with TipRanks
Follow Us
Palvella Therapeutics (PVLA)
NASDAQ:PVLA
PVLA Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
PVLA Stock 12 Month Forecast
Average Price Target
$79.75
▲(9.04% Upside)
| Highest Price Target$120.00 | Average Price Target$79.75 | Lowest Price Target$50.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$66→$90
Buy
23.05%
Upside
Reiterated
10/09/25
LifeSci Capital
$90
Buy
23.05%
Upside
Reiterated
10/08/25
Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potentials: We wanted to highlight a recent publicaon (LINK) by Gallagher et al. (Orphanet 2025), which provides a naonally representave, real-world prevalence esmates of cutaneous venous malformaons (CVMs) in the US. As a reminder, CVMs represent another high unmet need area of vascular anomalies, characterized by abnormal, dilated venous networks that manifest in the skin and subcutaneous ssues (note: lesions present with a fair amount of heterogeneity). These malformaons arise from disrupons in the process of vascular development, specifically affecng the venous system. CVM pathophysiology stems from somac mutaons in both TIE2 and PIK3CA genes.
Cantor Fitzgerald
$70→$120
Buy
64.07%
Upside
Reiterated
10/07/25
Truist Financial
$56→$80
Buy
9.38%
Upside
Reiterated
10/02/25
H.C. Wainwright
$75→$95
Buy
29.89%
Upside
Reiterated
09/25/25
Chardan Capital
$60→$73
Buy
-0.19%
Downside
Reiterated
09/25/25
JonesTrading
$56→$70
Buy
-4.29%
Downside
Reiterated
09/25/25
TD Cowen
$65
Buy
-11.13%
Downside
Reiterated
09/24/25
Stifel Nicolaus
$60→$80
Buy
9.38%
Upside
Reiterated
09/24/25
Oppenheimer
$85→$90
Buy
23.05%
Upside
Reiterated
09/24/25
Raymond James
$54
Buy
-26.17%
Downside
Initiated
08/06/25
Scotiabank
$50
Buy
-31.64%
Downside
Reiterated
07/22/25
Lucid Capital
$49
Buy
-33.01%
Downside
Initiated
03/18/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$66→$90
Buy
23.05%
Upside
Reiterated
10/09/25
LifeSci Capital
$90
Buy
23.05%
Upside
Reiterated
10/08/25
Positive Buy Rating for Palvella Therapeutics Driven by Promising CVM Treatment and Market Potentials: We wanted to highlight a recent publicaon (LINK) by Gallagher et al. (Orphanet 2025), which provides a naonally representave, real-world prevalence esmates of cutaneous venous malformaons (CVMs) in the US. As a reminder, CVMs represent another high unmet need area of vascular anomalies, characterized by abnormal, dilated venous networks that manifest in the skin and subcutaneous ssues (note: lesions present with a fair amount of heterogeneity). These malformaons arise from disrupons in the process of vascular development, specifically affecng the venous system. CVM pathophysiology stems from somac mutaons in both TIE2 and PIK3CA genes.
Cantor Fitzgerald
$70→$120
Buy
64.07%
Upside
Reiterated
10/07/25
Truist Financial
$56→$80
Buy
9.38%
Upside
Reiterated
10/02/25
H.C. Wainwright
$75→$95
Buy
29.89%
Upside
Reiterated
09/25/25
Chardan Capital
$60→$73
Buy
-0.19%
Downside
Reiterated
09/25/25
JonesTrading
$56→$70
Buy
-4.29%
Downside
Reiterated
09/25/25
TD Cowen
$65
Buy
-11.13%
Downside
Reiterated
09/24/25
Stifel Nicolaus
$60→$80
Buy
9.38%
Upside
Reiterated
09/24/25
Oppenheimer
$85→$90
Buy
23.05%
Upside
Reiterated
09/24/25
Raymond James
$54
Buy
-26.17%
Downside
Initiated
08/06/25
Scotiabank
$50
Buy
-31.64%
Downside
Reiterated
07/22/25
Lucid Capital
$49
Buy
-33.01%
Downside
Initiated
03/18/25
Best Analysts Covering Palvella Therapeutics
1 Month
xxx
Success Rate
4/4 ratings generated profit
Average Return
+31.40%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 100.00% of your transactions generating a profit, with an average return of +31.40% per trade.
3 Months
xxx
Success Rate
4/4 ratings generated profit
Average Return
+59.30%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +59.30% per trade.
1 Year
Success Rate
8/8 ratings generated profit
Average Return
+262.01%
reiterated a buy rating 23 days ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +262.01% per trade.
2 Years
xxx
Success Rate
8/8 ratings generated profit
Average Return
+262.01%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +262.01% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
PVLA Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
16
10
7
9
9
Buy
0
2
9
17
18
Hold
1
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
12
16
26
27
Each month's total comprises the sum of three months' worth of ratings.
PVLA Financial Forecast
PVLA Stock Forecast FAQ
What is PVLA’s average 12-month price target, according to analysts?
Based on analyst ratings, Palvella Therapeutics’s 12-month average price target is 79.75.
What is PVLA’s upside potential, based on the analysts’ average price target?
Palvella Therapeutics has 9.04% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is PVLA a Buy, Sell or Hold?
Palvella Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Palvella Therapeutics’s price target?
The average price target for Palvella Therapeutics is 79.75. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $50.00. The average price target represents 9.04% Increase from the current price of $73.14.
The highest analyst price target is $120.00 ,the lowest forecast is $50.00. The average price target represents 9.04% Increase from the current price of $73.14.
What do analysts say about Palvella Therapeutics?
Palvella Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of PVLA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.